As previously reported on January 27, Canaccord views Acadia Pharmaceuticals (ACAD) as presenting a solid opportunity and undervalued on approved products alone, with an underappreciated pipeline that is not in the stock price in any meaningful way at current levels. Canaccord reiterated its Buy rating and $32 price target on Acadia Pharmaceuticals shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals a solid opportunity here, says Canaccord
- ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment
- Acadia Pharmaceuticals sees 2025 net sales to exceed $1B, consensus $1.08B
- Acadia Pharmaceuticals price target raised to $40 from $35 at UBS
- Acadia Pharmaceuticals price target raised to $36 from $33 at Citi